Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Do you use biomarkers to improve risk prediction in patients with ADPKD during early disease stages?
Bais T, et al., PMID 40067938
Related Questions
When do you decide to initiate potassium binders for patients with hyperkalemia in the setting of CKD?
Would you recommend SGLT2 inhibitors for patients with sickle cell nephropathy and severely increased albuminuria despite the potential medication associated risk for vaso-occlusive crises?
Under what circumstances would you use tenapanor over more frequently prescribed phosphorus binders for managing hyperphosphatemia in CKD patients?
Do you advise your patients with CKD to consume a set amount of fluids daily in an attempt to prevent disease progression?
How would you approach management of retroperitoneal fibrosis causing ureteral compression that has already caused irreversible loss of kidney function?
Would you avoid a 24 hour urine collection for creatinine clearance measurement in a patient who is on fluid restriction?
What is your preferred potassium binder for patients with CKD and hyperkalemia that persists despite dietary potassium restriction?
Would you advocate for SGLT2 inhibitors if they are not fully covered by insurance in patients with moderately increased albuminuria (< 300 mg/g) who are on maximal dose ACEi/ARB?
Are there situations when you recommend initiating dialysis in patients with advanced chronic kidney disease, even if their symptoms are minimal and electrolytes are well controlled with medical management?
What is your approach for patients with advanced CKD who have bilateral Bosniak 2F cysts?
